^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Arzerra (ofatumumab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    04/19/2010
    Excerpt:
    ...Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy...Arzerra is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed CLL...Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.
    Secondary therapy:
    bendamustine; chlorambucil
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/26/2009
    Excerpt:
    ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of chronic lymphocytic leukemia (CLL) (1):...in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate....in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL....for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.
    Secondary therapy:
    chlorambucil
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of chronic lymphocytic leukemia (CLL)...for the treatment of patients with CLL refractory to fludarabine and alemtuzumab.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/03/2020
    Excerpt:
    FC + ofatumumab is approved for the treatment of patients with relapsed CLL and is included as an option for relapsed/refractory therapy, for patients <65 years without significant comorbidities.
    Secondary therapy:
    FC